Loading company
$5.79+3.5%Nov 12 close
Next earnings: December 22, 2026
Figures through December 31, 2025, from the 20-F filed April 30, 2026
Past performance
- 1W
- +1.6%
- 1M
- -12.4%
- 3M
- -50.4%
- 6M
- -66.9%
- 1Y
- -78.0%
- 5Y
- -98.0%
Built from Trinity Biotech plc’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$5.79+3.5%Nov 12 close
Next earnings: December 22, 2026
Figures through December 31, 2025, from the 20-F filed April 30, 2026
The themes Trinity Biotech is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$131.6BA+
SYKStryker Corp.$117.9BA+
EWEdwards Lifesciences Corporation$61.6BA+
GEHCGE Healthcare Technologies Inc.$37.5BA
GKOSGlaukos Corp$14.5BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now AEWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now AGEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now AGrade F
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 25 quarters of Trinity Biotech plc’s grade history. The other 23 go back to April 2018.